WO1996008238A1 - Use of paracellular absorption enhancers such as glucose for enhaincing the absorption of histamine h2-antagonists - Google Patents
Use of paracellular absorption enhancers such as glucose for enhaincing the absorption of histamine h2-antagonists Download PDFInfo
- Publication number
- WO1996008238A1 WO1996008238A1 PCT/EP1995/003572 EP9503572W WO9608238A1 WO 1996008238 A1 WO1996008238 A1 WO 1996008238A1 EP 9503572 W EP9503572 W EP 9503572W WO 9608238 A1 WO9608238 A1 WO 9608238A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- absorption
- histamine
- paracellular
- ranitidine
- glucose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- the present invention relates to a method for improving the absorption of drug substances, especially histamine H 2 -receptor antagonists, such as ranitidine, following oral administration.
- Histamine H 2 -receptor antagonists are preferably administered orally and, following oral administration, are absorbed paracellularly (i.e. through the tight junctions between cells of the intestinal mucosa). Although histamine H 2 - receptor antagonists are sufficiently well-absorbed following oral administration to effect treatment, enhancement of drug absorption would be advantageous since this would enable lower doses to be effective (enhanced extent of absorption) and would provide more rapid relief from symptoms (enhanced rate of absorption).
- Nellans Nallans (Nellans, H.N., Adv. Drug Delivery. 1991 ; 7:339-364) suggested that manipulation of the paracellular pathway could be used to enhance the oral delivery of small peptides and peptidomimetics.
- nutrients such as glucose on intestinal absorption are conflicting and inconclusive.
- Some in vitro models have suggested that glucose may enhance paracellular absorption.
- Nellans failed to observe any positive effect on absorption using lumenal glucose in vivo suggesting that positive in vitro results may be offset in vivo by secretory water flow such that little or no increase in absorption is observed.
- studies in intact rats with zidovudine suggest that D-glucose may have a positive effect on paracellular absorption of zidovudine.
- the present invention provides, in one aspect, the use of one or more paracellular absorption enhancers to significantly enhance the absorption of an orally administered drug substance, especially a histamine H 2 -receptor antagonist, such as ranitidine, or a physiologically acceptable salt thereof.
- a histamine H 2 -receptor antagonist such as ranitidine
- the invention provides the use of a histamine H 2 -receptor antagonist, or a physiologically acceptable salt thereof, and one or more paracellular absorption enhancers in the manufacture of medicaments for simultaneous, separate or sequential use in the treatment of gastrointestinal disorders, characterised in that the paracellular absorption enhancer(s) significantly enhances the absorption of the histamine H 2 -antagonist.
- the invention provides the use of an orally administerable pharmaceutical composition comprising a histamine H 2 -receptor antagonist, or a physiologically acceptable salt thereof, and one or more paracellular absorption enhancers for the manufacture of medicaments for the treatment of gastrointestinal disorders, characterised in that the paracellular absorption enhancer(s) significantly enhances the absorption of the histamine H 2 - antagonist.
- the invention provides a method of treatment of gastrointestinal disorders comprising orally administering to a sufferer an effective amount of a pharmaceutical composition comprising a histamine H 2 - receptor antagonist, or a physiologically acceptable salt thereof and one or more paracellular absorption enhancers, wherein the paracellular absorption enhancer significantly enhances the absorption of the histamine H 2 -antagonist.
- paracellular absorption enhancer encompasses any compound which enhances paracellular absorption.
- the paracellular absorption enhancers are those which occur naturally in nutrients.
- Paracellular absorption enhancers include carbohydrates such as monosaccharides, e.g. glucose, galactose, mannose, 3-0-methyl glucose, xylose, ribose, arabinose, ribulose, fructose and sorbose.
- the monosaccharides may be employed in either their D- or L- forms. Where the monosaccharide is naturally occuring, the naturally occuring form is preferred.
- Preferred paracellular absorption enhancers include glucose, e.g. D-glucose.
- a further preferred group of paracellular absorption enhancers includes galactose, e.g. D-galactose, mannose, e.g. D-mannose, 3-0-methyl glucose, e.g 3-0-methyl D-glucose, xylose, e.g. D-xylose.
- paracellular absorption enhancer(s) employed in the instant invention will be of the reversible type i.e. one whose absorption enhancement effect rapidly diminishes when it is no longer present at the site of action. All of the paracellular absorption enhancers specifically mentioned above are of the reversible type.
- the paracellular absorption enhancers may be used alone or in combination.
- gastrointestinal disorders encompasses a disease or other disorder of the gastrointestinal tract, including for example " acid indigestion, overindulgence of food or drink, acid stomach, sour stomach, waterbrash/regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn and meal-induced heartburn, gastritis and dyspepsia, duodenal and gastric ulceration, reflux oesophagitk and Zollinger-Ellison syndrome.
- Histamine H 2 -receptor antagonists which may be used in the instant invention include ranitidine, cimetidine, famotidine and nizatidine, and physiologically acceptable salts thereof.
- a preferred histamine H 2 -receptor antagonist for use in the instant invention is ranitidine and physiologically acceptable salts thereof.
- physiologically acceptable salts include salts formed with inorganic or organic acids such as the hydrochloride, hydrobromide, sulphate, acetate, maleate, succinate, citrate, tartrate, fumarate and ascorbate salts.
- a particularly preferred salt of ranitidine is the hydrochloride.
- ranitidine salts for use in the instant invention are those formed between ranitidine and a complex of bismuth with a carboxylic acid, particularly tartaric acid and, more especially, citric acid.
- a preferred salt of this class is ranitidine bismuth citrate.
- paracellular absorption enhancers enhance absorption of the histamine H 2 -receptor antagonists following dissociation from their salts.
- paracellular absorption enhancers have been found to significantly enhance the absorption of drug substances following oral administration. Surprisingly, both the extent and rate of absorption are enhanced. In the case of histamine H 2 -antagonists, the extent and rate of absorption are enhanced with the rate of absorption being increased to an unexpected, surprisingly large degree. Thus, in the case of ranitidine, rates of absorption in human volunteers have been increased by more than 80% compared with appropriate controls.
- the present invention provides a method of significantly enhancing the rate of absorption of a histamine H 2 -receptor antagonist, or a physiologically acceptable salt thereof, by simultaneous, separate or sequential administration of the histamine H 2 -receptor antagonist with one or more paracellular absorption enhancers.
- the drug substance e.g. the histamine H 2 -receptor antagonist, and one or more paracellular absorption enhancers may be co-administered in the form of separate pharmaceutical compositions for simultaneous and/or sequential use.
- the drug substance e.g. the histamine H 2 -receptor antagonist, and paracellular absorption enhancer(s) are administered as a single pharmaceutical composition for oral use comprising effective amounts of the active ingredients.
- the invention provides a pharmaceutical composition for oral use comprising a histamine H 2 -receptor antagonist, or a physiologically acceptable salt thereof, and one or more paracellular absorption enhancers.
- compositions according to the instant invention are effervescent tablets or granules, dispersible tablets and liquid syrups or suspensions. Effervescent tablets or granules are particularly preferred.
- the paracellular absorption enhancer is preferably galactose, mannose, 3-0-methyl glucose, xylose, ribose, arabinose, ribulose, fructose or sorbose.
- the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate).
- binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate
- lubricants e.g. magnesium stearate, talc or silica
- disintegrants e.g. potato starch or sodium starch glycollate
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl- ⁇ -hydroxybenzoates or sorbic acid).
- the preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
- Suitable methods of formulation are known in the art and include those methods described in UK Patent Specification Nos 2198352 (liquid preparations), 2219940 (effervescent tablets), 2218333 (ranitidine resinate), 2218336 (film- coated tablets), 2229094 (gelatin capsules), 2262445 (pulsed-release formulation), European Patent Specification Nos 349103, 459695, 473431 , 523847 and 538034 (chewable tablets), 542364 (controlled-release formulations), International Patent Specification Nos W092/21328 (chewable compositions), WO94/08560 (chewable tablets), W094/05260 (aqueous compositions), WO94/08576 (lipid-coated granules), Canadian Patent Specification No.
- the histamine H 2 -receptor antagonist and paracellular absorption enhancer(s) may, if desired, be administered in combination with one or more other therapeutic agents and formulated for administration by any convenient route in a conventional manner. Appropriate doses will be readily appreciated by those skilled in the art.
- the histamine H 2 -receptor antagonist and paracellular absorption enhancer(s) may be administered in combination with an antacid, such as calcium carbonate, an analgesic, an antiflatulent, a glucopryanoside, an alginate, a gastrointestinal motility agent, or an antihistamine, or a combination of these.
- suitable combination formulations are described in International Patent Specification ' Nos W092/00102, W093/12779 and W093/21932 (combination with antacids), W094/07541 (combination with (s)-ibuprofen salt), WO95/01784 (combination with glucopyranoside), WO95/01792 (combination with antihistamine), WO/01795 (combination with alginate), WO95/01803 (combination with gastrointestinal motility agent), European Patent Specification Nos 426479 (combination with analgesics) and 571217 (combination with antiflatulent) and UK Patent Specification Nos 2105193 (combination with NSAID's) and 2222772 (combination with alginate) which patent specifications are incorporated herein by reference.
- the paracellular absorption enhancer(s) may be incorporated into the above-mentioned formulations according to conventional procedures. It will be appreciated that the
- the ratio of drug substance, e.g. histamine H 2 -antagonist, to paracellular absorption enhancer(s) used in the method or compositions according to the invention is in the range of 1 :1 to 1 JOOO (by weight), e.g. 1 :4 to 1 :300, such as 1 :4 to 1 :150, especially 1 :80 or 1 :40 (by weight).
- the amount of histamine H 2 -receptor antagonist used according to the instant invention is preferably in the range of 10 to 800mg per dosage unit.
- the amount of ranitidine in the composition is preferably in the range of 10 to 600mg, more preferably 25 to 300mg, such as 25, 75, 125 or 150mg expressed as the weight of free base.
- the unit dose (for example contained in one tablet according to the invention) may be administered up to, for example, 12 times a day depending upon the unit dose used, the nature and severity of the conditions being treated, and the age and weight of the patient.
- Chewable tablets may be prepared using the conventional stages of mixing, granulation, drying, blending, compression and packing.
- Suitable swallow tablet cores may be prepared in a conventional manner, for example in a similar manner to that described in British Patent Specification No. 2084580 which is incorporated herein by reference.
- the required quantities of ranitidine or its salt, the paracellular absorption enhancer(s), a lubricant, such as magnesium stearate and optionally a pharmaceutically acceptable disintegrant, such as croscarmellose sodium are mixed and compressed into tablet cores.
- Swallow tablets are conventionally film-coated according to conventional procedures either by aqueous or organic techniques.
- a preferred film coat is described in British Patent specification No. 2218336 which is incorporated herein by reference.
- Effervescent formulations may be prepared in a conventional manner, for example in a similar manner to that described in UK patent specification no. 2219940 which is incorporated herein by reference.
- ranitidine or its salt, monoalkali metal citrate, and alkaline carbonate or bicarbonate may, for example, be blended with the paracellular absorption enhancer(s) and suitable excipients and, if desired, granulated. If the manufacturing process includes granulation, this should precede the addition of any flavouring agent(s). Any sweetening agents may be added either before or after granulation.
- Tablets may be prepared, for example, by compression of the powder blend or granulate, using a lubricant as an aid to tableting.
- Opaspray white K-1-7000 is a suspension of titanium dioxide and hydroxypropyl cellulose in industrial methylated spirits.
- Opadry Yellow Y S-1 -12606 is a mixture of hydroxypropyl methylcellulose 2910, titanium dioxide, triacetin and iron oxide yellow. Both Opaspray and Opadry are the tradenames of Colorcon Inc., West Point, Philadelphia, USA.
- the exemplified paracellular absorption enhancer may be replaced by any of the suitable paracellular or absorption enhancers described herein.
- D-glucose may be replaced by D- galactose, mannose, 3-0-methyl glucose or xylose.
- the amount of film coat applied per tablet may be less than that stated, depending on the efficiency of the process.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a method and pharmaceutical compositions for improving the absorption of drug substances, especially histamine H2-receptor antagonists, such as ranitidine, following oral administration.
Description
USE OF PARACELLULAR ABSORPTION ENHANCERS SUCH AS GLUCOSE FOR ENHANCING THE ABSORPTION OF HISTAMINE H2 - ANTAGONISTS
The present invention relates to a method for improving the absorption of drug substances, especially histamine H2-receptor antagonists, such as ranitidine, following oral administration.
Histamine H2-receptor antagonists are preferably administered orally and, following oral administration, are absorbed paracellularly (i.e. through the tight junctions between cells of the intestinal mucosa). Although histamine H2- receptor antagonists are sufficiently well-absorbed following oral administration to effect treatment, enhancement of drug absorption would be advantageous since this would enable lower doses to be effective (enhanced extent of absorption) and would provide more rapid relief from symptoms (enhanced rate of absorption).
It has been reported that certain monosaccharides and amino acids stimulate cytos eleton contraction to open up paracellular spaces to a sufficient size to pass molecules of a high molecular weight. Thus, Nellans (Nellans, H.N., Adv. Drug Delivery. 1991 ; 7:339-364) suggested that manipulation of the paracellular pathway could be used to enhance the oral delivery of small peptides and peptidomimetics. However, to date reports of the effects of nutrients such as glucose on intestinal absorption are conflicting and inconclusive. Some in vitro models have suggested that glucose may enhance paracellular absorption. However, Nellans (see above) failed to observe any positive effect on absorption using lumenal glucose in vivo suggesting that positive in vitro results may be offset in vivo by secretory water flow such that little or no increase in absorption is observed. However, studies in intact rats with zidovudine (Fleisher, D. et al. Pharm. Res.. 2, no. 9, Suppl., S154, 1990) suggest that D-glucose may have a positive effect on paracellular absorption of zidovudine.
There has been no suggestion to date that paracellular absorption enhancers may enhance the absorption of histamine H2-receptor antagonists or similar drugs.
A method of significantly enhancing the absorption of drug substances, especially histamine H2-receptor antagonists following oral administration has now been found.
Thus, the present invention provides, in one aspect, the use of one or more paracellular absorption enhancers to significantly enhance the absorption of an orally administered drug substance, especially a histamine H2-receptor antagonist, such as ranitidine, or a physiologically acceptable salt thereof.
In a further aspect the invention provides the use of a histamine H2-receptor antagonist, or a physiologically acceptable salt thereof, and one or more paracellular absorption enhancers in the manufacture of medicaments for simultaneous, separate or sequential use in the treatment of gastrointestinal disorders, characterised in that the paracellular absorption enhancer(s) significantly enhances the absorption of the histamine H2-antagonist.
In a further aspect the invention provides the use of an orally administerable pharmaceutical composition comprising a histamine H2-receptor antagonist, or a physiologically acceptable salt thereof, and one or more paracellular absorption enhancers for the manufacture of medicaments for the treatment of gastrointestinal disorders, characterised in that the paracellular absorption enhancer(s) significantly enhances the absorption of the histamine H2- antagonist.
In a further aspect, the invention provides a method of treatment of gastrointestinal disorders comprising orally administering to a sufferer an effective amount of a pharmaceutical composition comprising a histamine H2- receptor antagonist, or a physiologically acceptable salt thereof and one or more paracellular absorption enhancers, wherein the paracellular absorption enhancer significantly enhances the absorption of the histamine H2-antagonist.
The term "paracellular absorption enhancer" as used herein encompasses any compound which enhances paracellular absorption. For example, the paracellular absorption enhancers are those which occur naturally in nutrients. Paracellular absorption enhancers include carbohydrates such as monosaccharides, e.g. glucose, galactose, mannose, 3-0-methyl glucose,
xylose, ribose, arabinose, ribulose, fructose and sorbose. The monosaccharides may be employed in either their D- or L- forms. Where the monosaccharide is naturally occuring, the naturally occuring form is preferred.
Preferred paracellular absorption enhancers include glucose, e.g. D-glucose. A further preferred group of paracellular absorption enhancers includes galactose, e.g. D-galactose, mannose, e.g. D-mannose, 3-0-methyl glucose, e.g 3-0-methyl D-glucose, xylose, e.g. D-xylose.
It will be appreciated that the paracellular absorption enhancer(s) employed in the instant invention will be of the reversible type i.e. one whose absorption enhancement effect rapidly diminishes when it is no longer present at the site of action. All of the paracellular absorption enhancers specifically mentioned above are of the reversible type.
The paracellular absorption enhancers may be used alone or in combination.
International Patent Specification No. WO 94/08560 describes chewable ranitidine tablets having inter alia glucose as a chewable base. Chewable tablets according to WO 94/08560 are excluded from the present invention.
The term "gastrointestinal disorders" as used herein encompasses a disease or other disorder of the gastrointestinal tract, including for example" acid indigestion, overindulgence of food or drink, acid stomach, sour stomach, waterbrash/regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn and meal-induced heartburn, gastritis and dyspepsia, duodenal and gastric ulceration, reflux oesophagitk and Zollinger-Ellison syndrome.
It will be appreciated that reference to treatment is intended to include prophylaxis as well as the alleviation of established symptoms.
Histamine H2-receptor antagonists which may be used in the instant invention include ranitidine, cimetidine, famotidine and nizatidine, and physiologically acceptable salts thereof. A preferred histamine H2-receptor antagonist for use in the instant invention is ranitidine and physiologically acceptable salts thereof. Such physiologically acceptable salts include salts formed with inorganic or
organic acids such as the hydrochloride, hydrobromide, sulphate, acetate, maleate, succinate, citrate, tartrate, fumarate and ascorbate salts. A particularly preferred salt of ranitidine is the hydrochloride.
Further ranitidine salts for use in the instant invention are those formed between ranitidine and a complex of bismuth with a carboxylic acid, particularly tartaric acid and, more especially, citric acid. A preferred salt of this class is ranitidine bismuth citrate.
It will be appreciated that the paracellular absorption enhancers enhance absorption of the histamine H2-receptor antagonists following dissociation from their salts.
As mentioned hereinbefore, paracellular absorption enhancers have been found to significantly enhance the absorption of drug substances following oral administration. Surprisingly, both the extent and rate of absorption are enhanced. In the case of histamine H2-antagonists, the extent and rate of absorption are enhanced with the rate of absorption being increased to an unexpected, surprisingly large degree. Thus, in the case of ranitidine, rates of absorption in human volunteers have been increased by more than 80% compared with appropriate controls.
Thus, according to a further aspect, the present invention provides a method of significantly enhancing the rate of absorption of a histamine H2-receptor antagonist, or a physiologically acceptable salt thereof, by simultaneous, separate or sequential administration of the histamine H2-receptor antagonist with one or more paracellular absorption enhancers.
The drug substance, e.g. the histamine H2-receptor antagonist, and one or more paracellular absorption enhancers may be co-administered in the form of separate pharmaceutical compositions for simultaneous and/or sequential use. Preferably, the drug substance, e.g. the histamine H2-receptor antagonist, and paracellular absorption enhancer(s) are administered as a single pharmaceutical composition for oral use comprising effective amounts of the active ingredients.
Thus, according to a further aspect, the invention provides a pharmaceutical composition for oral use comprising a histamine H2-receptor antagonist, or a physiologically acceptable salt thereof, and one or more paracellular absorption enhancers.
Particularly suitable pharmaceutical compositions according to the instant invention are effervescent tablets or granules, dispersible tablets and liquid syrups or suspensions. Effervescent tablets or granules are particularly preferred.
When the pharmaceutical composition according to the invention is a chewable tablet containing ranitidine, the paracellular absorption enhancer is preferably galactose, mannose, 3-0-methyl glucose, xylose, ribose, arabinose, ribulose, fructose or sorbose.
For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well"known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl- β-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
Suitable methods of formulation are known in the art and include those methods described in UK Patent Specification Nos 2198352 (liquid preparations),
2219940 (effervescent tablets), 2218333 (ranitidine resinate), 2218336 (film- coated tablets), 2229094 (gelatin capsules), 2262445 (pulsed-release formulation), European Patent Specification Nos 349103, 459695, 473431 , 523847 and 538034 (chewable tablets), 542364 (controlled-release formulations), International Patent Specification Nos W092/21328 (chewable compositions), WO94/08560 (chewable tablets), W094/05260 (aqueous compositions), WO94/08576 (lipid-coated granules), Canadian Patent Specification No. 2068366 (taste-masked powder), United States Patent Specification Nos 5169864 and 5304571 (aqueous compositions) which patent specifications are incorporated herein by reference. The paracellular absorption enhancer(s) may be incorporated into the above-mentioned formulations according to conventional procedures.
The histamine H2-receptor antagonist and paracellular absorption enhancer(s) may, if desired, be administered in combination with one or more other therapeutic agents and formulated for administration by any convenient route in a conventional manner. Appropriate doses will be readily appreciated by those skilled in the art. For example, the histamine H2-receptor antagonist and paracellular absorption enhancer(s) may be administered in combination with an antacid, such as calcium carbonate, an analgesic, an antiflatulent, a glucopryanoside, an alginate, a gastrointestinal motility agent, or an antihistamine, or a combination of these. For example, suitable combination formulations are described in International Patent Specification' Nos W092/00102, W093/12779 and W093/21932 (combination with antacids), W094/07541 (combination with (s)-ibuprofen salt), WO95/01784 (combination with glucopyranoside), WO95/01792 (combination with antihistamine), WO/01795 (combination with alginate), WO95/01803 (combination with gastrointestinal motility agent), European Patent Specification Nos 426479 (combination with analgesics) and 571217 (combination with antiflatulent) and UK Patent Specification Nos 2105193 (combination with NSAID's) and 2222772 (combination with alginate) which patent specifications are incorporated herein by reference. The paracellular absorption enhancer(s) may be incorporated into the above-mentioned formulations according to conventional procedures.
It will be appreciated that the amount of paracellular absorption enhancer(s) employed in the instant invention is sufficient to provide an absorption enhancing effect.
Thus, the ratio of drug substance, e.g. histamine H2-antagonist, to paracellular absorption enhancer(s) used in the method or compositions according to the invention is in the range of 1 :1 to 1 JOOO (by weight), e.g. 1 :4 to 1 :300, such as 1 :4 to 1 :150, especially 1 :80 or 1 :40 (by weight).
The amount of histamine H2-receptor antagonist used according to the instant invention is preferably in the range of 10 to 800mg per dosage unit. For example, when ranitidine is employed, the amount of ranitidine in the composition is preferably in the range of 10 to 600mg, more preferably 25 to 300mg, such as 25, 75, 125 or 150mg expressed as the weight of free base.
The unit dose (for example contained in one tablet according to the invention) may be administered up to, for example, 12 times a day depending upon the unit dose used, the nature and severity of the conditions being treated, and the age and weight of the patient.
Chewable tablets may be prepared using the conventional stages of mixing, granulation, drying, blending, compression and packing.
Suitable swallow tablet cores may be prepared in a conventional manner, for example in a similar manner to that described in British Patent Specification No. 2084580 which is incorporated herein by reference. Thus, for example the required quantities of ranitidine or its salt, the paracellular absorption enhancer(s), a lubricant, such as magnesium stearate and optionally a pharmaceutically acceptable disintegrant, such as croscarmellose sodium, are mixed and compressed into tablet cores.
Swallow tablets are conventionally film-coated according to conventional procedures either by aqueous or organic techniques. A preferred film coat is described in British Patent specification No. 2218336 which is incorporated herein by reference.
Effervescent formulations may be prepared in a conventional manner, for example in a similar manner to that described in UK patent specification no. 2219940 which is incorporated herein by reference. Thus, ranitidine or its salt, monoalkali metal citrate, and alkaline carbonate or bicarbonate may, for example, be blended with the paracellular absorption enhancer(s) and suitable excipients and, if desired, granulated. If the manufacturing process includes granulation, this should precede the addition of any flavouring agent(s). Any sweetening agents may be added either before or after granulation. Tablets may be prepared, for example, by compression of the powder blend or granulate, using a lubricant as an aid to tableting.
The following are illustrations of non-limiting examples of pharmaceutical compositions according to the invention. Opaspray white K-1-7000 is a suspension of titanium dioxide and hydroxypropyl cellulose in industrial methylated spirits. Opadry Yellow Y S-1 -12606 is a mixture of hydroxypropyl methylcellulose 2910, titanium dioxide, triacetin and iron oxide yellow. Both Opaspray and Opadry are the tradenames of Colorcon Inc., West Point, Philadelphia, USA.
In the following examples, the exemplified paracellular absorption enhancer may be replaced by any of the suitable paracellular or absorption enhancers described herein. Thus, for example, D-glucose may be replaced by D- galactose, mannose, 3-0-methyl glucose or xylose.
Example 1
Chewable Tablet
Ingredient mg/tablet
Ranitidine HCI 28.0
D-galactose 2268.0
Aspartame 37.5
Povidone 50.0
Peppermint Flavour 41.5
Silica Gel 50.0
Magnesium Stearate 25.0
Isopropyl Alcohol + qs
+ not present in final product
Example 2 Swallow Tablet
Tablet Core mg/tablet
Ranitidine HCI 28.0
D-glucose 263.75
Croscarmellose Sodium Type A 6.00
Magnesium Stearate 2.25
Target compression weight 300mg
Film Coat % w/w Unit amounts (mg tablet)*
Methylhydroxypropyl Cellulose 4.0 11.3
Opaspray White K-1-7000 3.3 4.7
Isopropyl Alcohol ** 26.3 qs
Dichloromethane ** 66.4 qs
The amount of film coat applied per tablet may be less than that stated, depending on the efficiency of the process.
Not present in the final product.
Example 3 Swallow Tablet
Tablet Core Unit Amounts (mg/tablet)
Ranitidine HCI 28.000 Microcrystalline Cellulose 92.875 D-xylose 28.0 Magnesium Stearate 1 J25
Total Compression Weight 150.00
Film Coat Unit Amounts (mg/tablet)
Opadry Yellow YS-1 -12606 6.75 Purified Water " 42.34
** Removed during processing
Example 4 Effervescent Tablet
(a) (b) (c) (d) mg/ mg/ mg/ mg/ tablet tablet tablet tablet
Ranitidine HCI 168.0 168.0 168.0 84.0
D-glucose 3000.0 3000.0 3000.0 3000.0
Anhydrous Monosodium Citrate 840.0 838.0 935.0 467.5
Sodium Bicarbonate 836.0 834.0 267.0 133.5
Saccharin Sodium 11.0 - - -
Aspartame - 30.0 30.0 15.0
Polyvinylpyrrolidone 40.0 40.0 40.0 20.0
Sodium Benzoate 80.0 60.0 60.0 30.0
Lemon Flavour Powder 25.0 - - -
Orange Flavour Powder - 20.0 qs qs"
Grapefruit Flavour Powder - 10.0 qs qs Pharmaceutical Alcohol For Granulation
Example 5 Effervescent Granules
(a) (b) mg/sachet mg/sachet
Ranitidine HCI 168.0 84.0
D-glucose 3000.0 3000.0
Anhydrous Monosodium Citrate 618.72 309.36
Sodium Bicarbonate 615.78 307.89
Aspartame 22.50 11.25
Polyvinylpyrrolidone 52.50 26.25
Orange Flavour Powder 15.0 7.50
Grapefruit Flavour Powder 7.50 3.75 Pharmaceutical Alcohol For Granulation
Example 6 Oral Liquid
(a) (b)
Amount of ranitidine free base per 10ml 150mg 75mg
Ranitidine HCI 1.68g 8.4g
D-glucose 10.0g 10.0g
Ethanol 7.5g 7.5g
Potassium Dihydrogen Orthophosphate 0.095g 0.095g
Disodium Hydrogen Orthophosphate Anhydrous 0.350g 0.350g
Hydroxypropylmethylcellulose qs qs
Preservative qs qs
Sweetening Agents qs qs
Flavour qs qs
Purified water BP to 100ml 100ml
Biological Data
A crossover study in 8 healthy volunteers was carried out to investigate the effects of 0.0, 0.3, 1.0, and 3.0g of D-glucose on the rate and extent of absorption of ranitidine. Volunteers received on separate occasions a solution of ranitidine hydrochloride (75mg) and D-glucose (0.3, 1.0, or 3.0g) dissolved in
50ml of water followed by a further 150ml of tap water. Blood samples for determination of plasma ranitidine concentrations were taken up to 6 hours post dose.
A second crossover study in 8 healthy volunteers investigated the effects of 11 and 22g of D-glucose on the rate and extent of ranitidine absorption. This study used a solution of ranitidine hydrochloride (150mg) and D-glucose dissolved in 100ml water. Concentrations up to 10 hours post-dose were measured. The combined results from both studies are summarised below:
Dose of Dose of % Increase in D-glucose Ranitidine HCI Rate of Extent of
(g) (mg) Absorption3 Absorption"
0.3 75 16% 7%
1.0 75 19% 11%
3.0 75 "43% 19%
11 150 "70% 14%
22 150 "82% *17%
a measured using partial area under the plasma ranitidine concentration-time cure from zero to 2 hours post dose.
b measured using total area under the curve from zero to the time of last quantifiable plasma ranitidine concentration.
* statistically significant p<0.05
" statistically significant p<0.01
Claims
1. A pharmaceutical composition for oral use comprising a histamine H2-receptor antagonist, or a physiologically acceptable salt thereof, and one or more paracellular absorption enhancers.
2. A composition according to claim 1 wherein the paracellular absorption enhancer is glucose.
3. A composition according to claim 1 wherein the paracellular absorption enhancer is selected from galactose, mannose, 3-0-methyl glucose, xylose, ribose, arabinose, ribulose, fructose and sorbose.
4. A composition according to claim 3 wherein the paracellular absorption enhancer is selected from galactose, mannose, 3-0-methyl glucose and xylose.
5. A composition according to any of claims 1 to 4 wherein the histamine H2- receptor antagonist is ranitidine or a physiologically acceptable salt thereof.
6. A composition according to claim 5 containing ranitidine hydrochloride.
7. A composition according to claim 5 or 6 containing 25 to 300mg ranitidine expressed as the weight of free base.
8. The use of a pharmaceutical composition as defined in any of claims 1 to 7 for the manufacture of a medicament for the treatment of gastrointestinal disorders, characterised in that the paracellular absorption enhancer(s) significantly enhances the absorption of the histamine H2-antagonist.
9. A method of treatment of gastrointestinal disorders comprising orally administering to a sufferer an effective amount of a pharmaceutical composition as defined in any of claims 1 to 7 wherein the paracellular absorption enhancer significantly enhances the absorption of the histamine H2-antagonist.
10. The use of a histamine H2-receptor antagonist, or a physiologically acceptable salt thereof, and one or more paracellular absorption enhancers in the manufacture of medicaments for simultaneous, separate or sequential use in the treatment of gastrointestinal disorders, characterised in that the paracellular absoφtion enhancer(s) significantly enhances the absoφtion of the histamine H2-antagonist.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8509897A JPH10511637A (en) | 1994-09-14 | 1995-09-12 | Use of paracellular absorption enhancers, such as glucose, to enhance histamine H 2 -antagonist absorption |
| AU35656/95A AU3565695A (en) | 1994-09-14 | 1995-09-12 | Use of paracellular absorption enhancers such as glucose for enhaincing the absorption of histamine h2-antagonists |
| EP95932713A EP0777470A1 (en) | 1994-09-14 | 1995-09-12 | Use of paracellular absorption enhancers such as glucose for enhancing the absorption of histamine h2-antagonists |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9418530.3 | 1994-09-14 | ||
| GB9418530A GB9418530D0 (en) | 1994-09-14 | 1994-09-14 | Medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996008238A1 true WO1996008238A1 (en) | 1996-03-21 |
Family
ID=10761317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1995/003572 WO1996008238A1 (en) | 1994-09-14 | 1995-09-12 | Use of paracellular absorption enhancers such as glucose for enhaincing the absorption of histamine h2-antagonists |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0777470A1 (en) |
| JP (1) | JPH10511637A (en) |
| AU (1) | AU3565695A (en) |
| GB (1) | GB9418530D0 (en) |
| IL (1) | IL115254A0 (en) |
| WO (1) | WO1996008238A1 (en) |
| ZA (1) | ZA957628B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997033565A1 (en) * | 1996-03-13 | 1997-09-18 | Glaxo Group Limited | Nucleoside compositions containing paracellular absorption enhancers |
| EP1206249A1 (en) * | 1999-08-04 | 2002-05-22 | Ranbaxy Laboratories, Ltd. | Hydrodynamically balancing oral drug delivery system |
| AU2007216671B2 (en) * | 2007-07-09 | 2009-07-16 | Cypress Pharmaceutical, Inc. | Pleasant-tasting ranitidine formulation |
| US7709529B2 (en) | 2002-08-01 | 2010-05-04 | Eisai Inc. | Treatment of cancer with glutamine |
| CN110251523A (en) * | 2019-05-30 | 2019-09-20 | 吉林农业大学 | It is a kind of to strengthen attention and the neurasthenic preparation of alleviation using glucuronic acid as synergist |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992004893A1 (en) * | 1990-09-13 | 1992-04-02 | Smithkline Beecham Corporation | Non-aqueous liquid oral suspensions |
| US5219563A (en) * | 1988-05-11 | 1993-06-15 | Glaxo Group Limited | Drug adsorbates |
| WO1994008560A1 (en) * | 1992-10-13 | 1994-04-28 | Glaxo Group Limited | Ranitidine chewable tablets |
-
1994
- 1994-09-14 GB GB9418530A patent/GB9418530D0/en active Pending
-
1995
- 1995-09-12 EP EP95932713A patent/EP0777470A1/en not_active Withdrawn
- 1995-09-12 ZA ZA957628A patent/ZA957628B/en unknown
- 1995-09-12 AU AU35656/95A patent/AU3565695A/en not_active Abandoned
- 1995-09-12 WO PCT/EP1995/003572 patent/WO1996008238A1/en not_active Application Discontinuation
- 1995-09-12 JP JP8509897A patent/JPH10511637A/en active Pending
- 1995-09-12 IL IL11525495A patent/IL115254A0/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219563A (en) * | 1988-05-11 | 1993-06-15 | Glaxo Group Limited | Drug adsorbates |
| WO1992004893A1 (en) * | 1990-09-13 | 1992-04-02 | Smithkline Beecham Corporation | Non-aqueous liquid oral suspensions |
| WO1994008560A1 (en) * | 1992-10-13 | 1994-04-28 | Glaxo Group Limited | Ranitidine chewable tablets |
Non-Patent Citations (4)
| Title |
|---|
| DAVID FLEISHER ET AL.: "Nutrient influences on rat intestinal phenytoin uptake", PHARM. RES., vol. 6, no. 4, pages 332 - 337 * |
| G.FRICKER ET AL.: "Enteral absorption of octreotide: Modulation of intestinal permeability by distinct carbohydrates", J.PHARM.EXP.THER., vol. 274, no. 2, pages 826 - 832 * |
| JENNIFER B. DRESSMAN ET AL.: "Gastrointestinal parameters that influence oral medications", J.PHARM.SCI., vol. 82, no. 3, pages 857 - 872 * |
| ZHENZE HU ET AL.: "The intestinal uptake of "enzymatically-stable" peptide drugs in rats as influenced by D-glucose in situ", LIFE SCIENCES, vol. 54, no. 25, pages 1977 - 1985 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997033565A1 (en) * | 1996-03-13 | 1997-09-18 | Glaxo Group Limited | Nucleoside compositions containing paracellular absorption enhancers |
| EP1206249A1 (en) * | 1999-08-04 | 2002-05-22 | Ranbaxy Laboratories, Ltd. | Hydrodynamically balancing oral drug delivery system |
| EP1206249A4 (en) * | 1999-08-04 | 2004-12-22 | Ranbaxy Lab Ltd | Hydrodynamically balancing oral drug delivery system |
| US7709529B2 (en) | 2002-08-01 | 2010-05-04 | Eisai Inc. | Treatment of cancer with glutamine |
| AU2007216671B2 (en) * | 2007-07-09 | 2009-07-16 | Cypress Pharmaceutical, Inc. | Pleasant-tasting ranitidine formulation |
| CN110251523A (en) * | 2019-05-30 | 2019-09-20 | 吉林农业大学 | It is a kind of to strengthen attention and the neurasthenic preparation of alleviation using glucuronic acid as synergist |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10511637A (en) | 1998-11-10 |
| EP0777470A1 (en) | 1997-06-11 |
| GB9418530D0 (en) | 1994-11-02 |
| ZA957628B (en) | 1996-06-12 |
| AU3565695A (en) | 1996-03-29 |
| IL115254A0 (en) | 1995-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2453117C (en) | Oral dosage forms comprising a benzimidazole and buffer | |
| US6780882B2 (en) | Substituted benzimidazole dosage forms and method of using same | |
| CA2473669C (en) | Use and preparation of dosage forms containing benzimidazole derivatives and a buffer | |
| US5593685A (en) | Ranitidine compositions | |
| AU2002330863A1 (en) | Novel substituted benzimidazole dosage forms and method of using same | |
| US5989588A (en) | Methods and compositions for preventing and treating heartburn | |
| KR100238565B1 (en) | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress | |
| WO1996008238A1 (en) | Use of paracellular absorption enhancers such as glucose for enhaincing the absorption of histamine h2-antagonists | |
| JP2007503427A (en) | Composition for treating medical conditions requiring suppression of gastric acid secretion | |
| JPH0656677A (en) | Antacid composition | |
| WO1995016446A1 (en) | Ranitidine compositions | |
| AU677108B2 (en) | Ranitidine and calcium carbonate pharmaceutical combination product | |
| AU690664B2 (en) | Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion | |
| CA2594185C (en) | Solid dosage forms comprising a substituted benzimidazole derivative and a buffer | |
| TWI309168B (en) | A solid pharmaceutical composition of proton pump inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1995932713 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1995932713 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1995932713 Country of ref document: EP |